BioMarin Pharmaceutical stock is trading -14.93% below its average target price of $110.56 after dropping -2.6% during today's afternoon session. Analysts are giving the large-cap Pharmaceutical company an average rating of buy and target prices ranging from $78.0 to $170.0 per share.
The stock has a very low short interest at 1.8%, and a short ratio of 1.45. The company's insiders own 0.58% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 99.0% of BioMarin Pharmaceutical's shares being owned by this investor type.
Institutions Invested in BioMarin Pharmaceutical
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | Primecap Management Company | 10% | 18,406,539 | $1,731,135,049 |
| 2023-09-30 | Vanguard Group Inc | 9% | 17,701,210 | $1,664,798,854 |
| 2023-09-30 | Blackrock Inc. | 8% | 14,607,187 | $1,373,805,981 |
| 2023-09-30 | Dodge & Cox Inc | 8% | 14,153,503 | $1,331,137,000 |
| 2023-09-30 | State Street Corporation | 3% | 6,458,729 | $607,443,482 |
| 2023-09-30 | Capital Research Global Investors | 3% | 6,017,970 | $565,990,096 |
| 2023-09-30 | Barclays Plc | 3% | 5,573,157 | $524,155,432 |
| 2023-09-30 | Ameriprise Financial, Inc. | 3% | 5,163,949 | $485,669,419 |
| 2023-09-30 | Viking Global Investors, L.P. | 2% | 4,215,456 | $396,463,649 |
| 2023-09-30 | Avoro Capital Advisors LLC | 2% | 3,850,000 | $362,092,511 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on BioMarin Pharmaceutical.
